<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="health burden worldwide. Vaccination is the best way to prevent" exact="influenza" post="virus infections. However, conventional vaccines are only effective for"/>
 <result pre="a short period of time due to the propensity of" exact="influenza" post="viruses to undergo antigenic drift and antigenic shift. The"/>
 <result pre="have been discovered that may serve as means to suppress" exact="influenza" post="viral infection and allow the process of natural immunity"/>
 <result pre="approach assumes a robust tool that could aid control of" exact="influenza" post="viruses. In this review, we comment on some improvements"/>
 <result pre="viruses. In this review, we comment on some improvements in" exact="influenza" post="management and promising vaccine development platforms with an emphasis"/>
 <result pre="coupled with the use of antivirals in the management of" exact="influenza" post="infection. Influenza virus vaccines passive immunization immunotherapeutics 1. Introduction"/>
 <result pre="nearly a million morbidities and half-a-million mortalities. Four types of" exact="influenza" post="viruses (i.e., A, B, C, and D) have been"/>
 <result pre="humans) and D (isolated from cattle) are less common; typically," exact="influenza" post="virus C is associated with less severe illness [1,2]."/>
 <result pre="associated with less severe illness [1,2]. On the other hand," exact="influenza" post="viruses A (infecting avian and mammals including human) and"/>
 <result pre="humans and seals) account for the annual global burden of" exact="influenza" post="[3,4]. The persistence of influenza viruses A and B"/>
 <result pre="the annual global burden of influenza [3,4]. The persistence of" exact="influenza" post="viruses A and B has been attributed to their"/>
 <result pre="ability to evolve rapidly. Antigenic variabilities are also common with" exact="influenza" post="viruses A and B, and these are partly as"/>
 <result pre="by Fergusson et al. revealed that antigenic drifts in seasonal" exact="influenza" post="viruses (H3, H1, and B) were estimated at fixation"/>
 <result pre="supports the idea that antigenic drifts occur more frequently in" exact="influenza" post="A viruses than influenza B viruses. In addition, high"/>
 <result pre="antigenic drifts occur more frequently in influenza A viruses than" exact="influenza" post="B viruses. In addition, high mutation rates cause a"/>
 <result pre="rates cause a tremendous impact in efficacy of the seasonal" exact="influenza" post="vaccines which comprise forecasted strains [9]. For instance, gain"/>
 <result pre="the same study, the authors further observed that the 1968" exact="influenza" post="epidemic strain (A/VIC/3/75) that had N63 (known glycosylation site),"/>
 <result pre="in potential cause of vaccine failure. Antigenic shift also allows" exact="influenza" post="viruses to escape pre-existing immunity [11]. This mechanism is"/>
 <result pre="reliant on the ability of the eight genomic fragments of" exact="influenza" post="viruses to reassort with genomes of other influenza viral"/>
 <result pre="fragments of influenza viruses to reassort with genomes of other" exact="influenza" post="viral subtypes. It occurs when two or more of"/>
 <result pre="viral subtypes or strains [11,12]. Thus, antigenic shifts (principally underlying" exact="influenza" post="A virus pandemics) and antigenic drifts (underlying vaccine mismatches"/>
 <result pre="virus pandemics) and antigenic drifts (underlying vaccine mismatches against seasonal" exact="influenza" post="A and B viruses) and a wide host-range (for"/>
 <result pre="influenza A and B viruses) and a wide host-range (for" exact="influenza" post="A viruses) all contribute to the recurring cases of"/>
 <result pre="influenza A viruses) all contribute to the recurring cases of" exact="influenza" post="all year round [13,14]. Furthermore, antigenic drifts and shifts"/>
 <result pre="immediate need for highly efficacious intervention. We review here vital" exact="influenza" post="management strategies, novel vaccine and antiviral development approaches with"/>
 <result pre="prospects. 2. Current Influenza Vaccines Three types of vaccines against" exact="influenza" post="are currently used worldwide including inactivated influenza vaccine (IIV),"/>
 <result pre="of vaccines against influenza are currently used worldwide including inactivated" exact="influenza" post="vaccine (IIV), live-attenuated influenza vaccine (LAIV) and influenza virus"/>
 <result pre="are currently used worldwide including inactivated influenza vaccine (IIV), live-attenuated" exact="influenza" post="vaccine (LAIV) and influenza virus subunit vaccine: each of"/>
 <result pre="including inactivated influenza vaccine (IIV), live-attenuated influenza vaccine (LAIV) and" exact="influenza" post="virus subunit vaccine: each of which has its own"/>
 <result pre="in the nasopharynx elicit immune response that epitomizes a natural" exact="influenza" post="infection. For this reason, LAIV has shown some superiority"/>
 <result pre="about 0.7 μg/ mL [24,25,26]. The development of the subunit" exact="influenza" post="vaccines, which often comprise of influenza virus HA that"/>
 <result pre="development of the subunit influenza vaccines, which often comprise of" exact="influenza" post="virus HA that have been purified following protein expression"/>
 <result pre="Besides, the subunit vaccine also offers desirable protection against seasonal" exact="influenza" post="viruses; but its downside being higher dosage requirement at"/>
 <result pre="both the LAIV and IIV are cocktails of circulating seasonal" exact="influenza" post="viruses. Mainly three viruses, i.e., A (H1N1) pdm09, A"/>
 <result pre="i.e., A (H1N1) pdm09, A (H3N2), and the pre-determined dominant" exact="influenza" post="B lineage (whether Yamagata or Victoria) are the constituents"/>
 <result pre="Yamagata or Victoria) are the constituents of the seasonal trivalent" exact="influenza" post="vaccines (TIV). Subunit vaccines are also formulated as TIV,"/>
 <result pre="[29]. However, it became necessary to feature both lineages of" exact="influenza" post="B viruses based on the current global epidemiology of"/>
 <result pre="influenza B viruses based on the current global epidemiology of" exact="influenza" post="as recommended by Ambrose and Levin in 2012. This"/>
 <result pre="Levin in 2012. This resulted in the advancement of quadrivalent" exact="influenza" post="vaccines (QIV) containing the pre-determined representatives of both Yamagata"/>
 <result pre="(QIV) containing the pre-determined representatives of both Yamagata and Victoria" exact="influenza" post="B virus lineages, in addition to the two pre-determined"/>
 <result pre="virus lineages, in addition to the two pre-determined circulating seasonal" exact="influenza" post="A subtypes [30]. This approach of vaccine preparation thus"/>
 <result pre="a constant reformulation to maintain desirable efficacy limits during an" exact="influenza" post="season [30,31]. 3. Use of the Seasonal Influenza Vaccines"/>
 <result pre="with influenza, the US CDC advocates the use of seasonal" exact="influenza" post="vaccines in all persons &amp;gt;6 months prior to the"/>
 <result pre="other hand, the WHO extends recommendations for the use of" exact="influenza" post="vaccination in the persons categorized as high-risk, which comprises"/>
 <result pre="Africa and Asia, there are either limited or no established" exact="influenza" post="vaccination policies. Thus, restricted availability of influenza vaccines makes"/>
 <result pre="or no established influenza vaccination policies. Thus, restricted availability of" exact="influenza" post="vaccines makes vaccinations quite uncommon to these populations. Perhaps,"/>
 <result pre="acquiring vaccines annually or still, the reduced efficacy of the" exact="influenza" post="vaccines, as have been critically assessed by Xu et"/>
 <result pre="been made for twice-dose vaccination due to frequencies of seasonal" exact="influenza" post="occurrences, all year round [34]. Although poor vaccine coverage"/>
 <result pre="Duque et al., upon investigation on the availability of seasonal" exact="influenza" post="vaccines, there are still no clearly underpinned core reasons"/>
 <result pre="clearly underpinned core reasons [35]. Therefore, the improved efficacy of" exact="influenza" post="vaccines would also contribute to enhanced vaccine coverage in"/>
 <result pre="in Africa and Asia. 4. Novel Influenza Vaccine Platforms Rapid" exact="influenza" post="virus evolution and yearly vaccine reformulations make the stockpiling"/>
 <result pre="but without their complete set of genetic materials. A typical" exact="influenza" post="VLP has the HA, NA, and the matrix protein"/>
 <result pre="a range of viruses including human papilloma virus (HPV) and" exact="hepatitis" post="B virus (HBV) or hepatitis E virus (HEV) as"/>
 <result pre="human papilloma virus (HPV) and hepatitis B virus (HBV) or" exact="hepatitis" post="E virus (HEV) as discussed by Zhao et al."/>
 <result pre="these examples have completely different &quot;biologies�? when compared with the" exact="influenza" post="virus, rapid advances and need for a new vaccine"/>
 <result pre="a new vaccine platform are generating some promising data for" exact="influenza" post="VLPs. For instance, to overcome challenges raised by rapid"/>
 <result pre="influenza VLPs. For instance, to overcome challenges raised by rapid" exact="influenza" post="evolution Gao et al. attempted to generate VLPs with"/>
 <result pre="which increased murine mucosal immunity to both drifted and homologous" exact="influenza" post="A (H3N2) viruses, as well as the longevity of"/>
 <result pre="a platform for improved formulation of multivalent (containing heterologous epitopes)" exact="influenza" post="vaccine. 6. Computationally Optimized Broadly Reactive Antigen Vaccines (COBRA)"/>
 <result pre="was fitter in eggs, is good news for generation of" exact="influenza" post="vaccines in eggs [48]. Alternatively, replication-incompetent viruses can be"/>
 <result pre="trivalent vaccine which revealed protection of vaccinees against the seasonal" exact="influenza" post="viruses [49,50]. This platform has also paved way for"/>
 <result pre="has also paved way for the generation of single-cycle replicating" exact="influenza" post="viruses as vaccine candidates and have shown similar or"/>
 <result pre="protection than the conventional LAIV [51,52,53]. The main reasons synthetic" exact="influenza" post="vaccines remain promising is due to their ability to"/>
 <result pre="children during a pandemic revealed a cross-reactivity pattern to historical" exact="influenza" post="A (H1N1) isolates [57]. A conserved epitope situated on"/>
 <result pre="epitope in a murine challenge against diverse strains of the" exact="influenza" post="A (H1N1) [57]. Another universal vaccine candidate currently undergoing"/>
 <result pre="HA; three, to NP and one, to M1) of several" exact="influenza" post="virus strains, and this vaccine has been shown to"/>
 <result pre="(APCs) to efficiently involve the T-cell arm of immunity to" exact="influenza" post="virus clearance. One of the examples is the work"/>
 <result pre="of Fonteneau and colleagues who showed that after exposure to" exact="influenza" post="virus, dendritic cells (DCs) (both CD11c+ DCs and plasmacytoid"/>
 <result pre="10. Nanoparticle-Based Influenza Vaccines Continued efforts to develop a universal" exact="influenza" post="vaccine has driven the use of self-assembling monomeric ion-carrier"/>
 <result pre="vaccines displaying multivalent HA from 8 diverse strains of H1N1" exact="influenza" post="A viruses, were shown to induce broadly protective antibodies"/>
 <result pre="affording protection of mice challenged with virulent strain of an" exact="influenza" post="virus [63,64]. Intranasal administration of polylactic-co-glycolic acid (PLGA) nanoparticle"/>
 <result pre="[63,64]. Intranasal administration of polylactic-co-glycolic acid (PLGA) nanoparticle conjugated to" exact="influenza" post="A (H1N1) conserved peptides as a vaccine were also"/>
 <result pre="in mice that were immunized prior to challenge with specific" exact="influenza" post="A viruses [67]. Though a promising influenza vaccine platform,"/>
 <result pre="challenge with specific influenza A viruses [67]. Though a promising" exact="influenza" post="vaccine platform, high-throughput nanoparticle-based vaccines approaches that will facilitate"/>
 <result pre="nanoparticle-based vaccines approaches that will facilitate replacement of the seasonal" exact="influenza" post="vaccines are still to be developed [68]. 11. Viral-Vectored"/>
 <result pre="the humoral and cellular immunity [69]. Use of the modified" exact="vaccinia virus" post="Ankara (MVA) as a vector, incorporating influenza NP and"/>
 <result pre="the modified vaccinia virus Ankara (MVA) as a vector, incorporating" exact="influenza" post="NP and M1 proteins, has shown potent induction of"/>
 <result pre="NP and M1 proteins, has shown potent induction of both" exact="influenza" post="virus-specific humoral and cell-mediated responses leading to the phase"/>
 <result pre="to the phase II clinical trial [70,71]. An Adenovirus vectored" exact="influenza" post="vaccine has equally shown a strong induction of influenza"/>
 <result pre="vectored influenza vaccine has equally shown a strong induction of" exact="influenza" post="virus HA-stalk cross-reactive antibodies in mice [72]. Recently, Lingel"/>
 <result pre="mice [72]. Recently, Lingel et al. expressed multivalent adenovirus vectored" exact="influenza" post="virus vaccine (that comprise the consensus sequences of divergent"/>
 <result pre="administration in mice conferred protection of mice in a lethal" exact="influenza" post="virus challenge experiment [73]. This provides an avenue for"/>
 <result pre="baculovirus, Newcastle disease virus, pox virus, parainfluenza virus and vesicular" exact="stomatitis" post="virus, are other vectors that have also been proposed"/>
 <result pre="vaccines [74]. 12. Current Influenza Managing Antivirals Management of ongoing" exact="influenza" post="infection currently requires the use of antiviral drugs. Two"/>
 <result pre="antiviral drugs. Two drug classes approved for the control of" exact="influenza" post="infections include the adamantanes (Amantadines and Rimantadines) and NA"/>
 <result pre="is otherwise responsible for newly generated virion dissemination [75,76,77,78]. However," exact="influenza" post="viruses resistant to both the adamantanes and neuraminidase inhibitors"/>
 <result pre="Additionally, lack of data suggesting antiviral efficacy against highly pathogenic" exact="avian influenza" post="viruses (HPAI), i.e., H5N1 remains an important issue in"/>
 <result pre="lack of data suggesting antiviral efficacy against highly pathogenic avian" exact="influenza" post="viruses (HPAI), i.e., H5N1 remains an important issue in"/>
 <result pre="is imperative to note that there are still NA inhibitor-sensitive" exact="influenza" post="A viruses in circulation, and this drug class can"/>
 <result pre="Management Therapies 13.1. Next-Generation Antivirals Against Influenza The burden of" exact="influenza" post="requires identification of a novel compounds that have the"/>
 <result pre="the airways [89]. This inhibits the initial attachment of the" exact="influenza" post="virus HA that recognizes Neu5Ac in the α(2, 3)-"/>
 <result pre="shown to inhibit H1N1pdm09, H3N2, and H5N1 viruses [91,92,93]. Besides" exact="influenza" post="viruses, other sialic acid-dependent viruses such as human metapneumovirus"/>
 <result pre="These metabolites have been shown to inhibit the maturation of" exact="influenza" post="HA by blocking the trafficking and insertion of HA"/>
 <result pre="a licensed anthelminthic drug that has been repurposed to ameliorate" exact="influenza" post="due to its broad range of protection efficiency against"/>
 <result pre="influenza due to its broad range of protection efficiency against" exact="influenza" post="viruses in a phase II b/III clinical trial [95]."/>
 <result pre="b/III clinical trial [95]. The antiviral, JNJ-63623872 (Pimodivir) is non-nucleoside" exact="influenza" post="virus PB2 inhibitor, which binds a conserved domain on"/>
 <result pre="binds a conserved domain on the polymerase subunit, PB2 of" exact="influenza" post="A viruses and thereby inhibiting host cap-snatching (a perquisite"/>
 <result pre="pre-approval trial (of Pimodivir) for the treatment of patients with" exact="influenza" post="virus A (H7N9) infection, has been allowed. In 2002,"/>
 <result pre="was shown to have a selective index over 2000 for" exact="influenza" post="viruses, with no detectable cytotoxicity in vitro [101]. Trials"/>
 <result pre="[101]. Trials of T-705 in mice confirmed both selectivity to" exact="influenza" post="viruses and protection as an anti-influenza virus therapeutic agent."/>
 <result pre="noro- and flavi-viruses [106,107,108,109]. In summary, T-705 is effective against" exact="influenza" post="viruses in group 1 such as H1N1pdm09, H5N1 and"/>
 <result pre="H1N1pdm09 virus strain [111] Efficacy of T-705 for treatment of" exact="influenza" post="has thus warranted its advancement through phase III and"/>
 <result pre="shown to act as a selective cap-dependent endonuclease inhibitor of" exact="influenza" post="viruses’ (both A and B) polymerase subunit PA. The"/>
 <result pre="phase I trial [113]. The overall optimal performance against uncomplicated" exact="influenza" post="among adults and adolescents, was shown during phase II"/>
 <result pre="the US as Xofluxa, for the treatment of acute uncomplicated" exact="influenza" post="among ≥12 years [115]. Arbidol (Umifenovir) is another influenza-limiting"/>
 <result pre="originally developed in Russia and was found to potently inhibit" exact="influenza" post="virus fusion with susceptible cell membranes, followed by interferon"/>
 <result pre="interferon induction [118]. Like other broad-spectrum antivirals discussed earlier, besides" exact="influenza" post="viruses, Arbidol has been shown to efficiently suppress other"/>
 <result pre="and the flaviviruses (Zika virus, West Nile virus and Tick-borne" exact="encephalitis" post="virus) [119,120,121]. Currently, phase III trial of the Arbidol"/>
 <result pre="of 2017, Ingavirin has been approved for the treatment of" exact="influenza" post="and other viral causes of acute respiratory illness, in"/>
 <result pre="Management of Influenza The need for new strategies to control" exact="influenza" post="infections has led to the investigations of antibody therapy"/>
 <result pre="virus infections [125,126]. The feasibility of immunotherapy for rapidly evolving" exact="influenza" post="was attained upon the discovery of broadly neutralizing antibody"/>
 <result pre="as well as C179 was later found to neutralize only" exact="influenza" post="A viruses with group 1 HA. Similarly, another potential"/>
 <result pre="anti-H5N1 antibody could protect mice against a lethal challenge of" exact="influenza" post="H5N1 [133]. Such an example shows that use of"/>
 <result pre="Such an example shows that use of passive immunotherapy during" exact="influenza" post="outbreaks could complement the use of available antivirals that"/>
 <result pre="[136]. Wohlbold et al. also realized the importance of the" exact="influenza" post="HA stalk as a good vaccine target when they"/>
 <result pre="immunized with three tandem copies of M2e, fused with the" exact="hepatitis" post="B virus (HBV) core fusion protein) to show Fc-dependent"/>
 <result pre="for RSV with the commercial immunotherapy palivizumab, antibody-based therapies with" exact="influenza" post="antibodies could aid most susceptible populations including infants, which"/>
 <result pre="in mice (who received the construct intramuscularly) during a pathogenic" exact="influenza" post="virus (H1, H2, and H5) challenge [144]. Their experiments"/>
 <result pre="immuno-prophylaxis and -therapeutics have more prospects in effective intermediation of" exact="influenza" post="outbreaks and production of specific influenza vaccines, noting that"/>
 <result pre="in effective intermediation of influenza outbreaks and production of specific" exact="influenza" post="vaccines, noting that the broadly-reacting antibodies have the capacity"/>
 <result pre="antibody-dependent cell lysis (ADCL) are well-studied in the context of" exact="influenza" post="viruses. ADCC, which mainly involves destruction of infected cells"/>
 <result pre="has been observed for murine antibodies weakly interacting with cognate" exact="influenza" post="M2e [147]. Similarly, virus replication in mice was shown"/>
 <result pre="infected mice that either received anti-influenza serum before or after" exact="influenza" post="infection, when neutrophils were retained and not inhibited by"/>
 <result pre="ADCL is another mechanism that could augment the killing of" exact="influenza" post="viruses as observed by Terajima et al., realizing that"/>
 <result pre="emphasize the therapeutic capacity of novel monoclonal antibodies in combating" exact="influenza" post="infection, and speculate that, in addition to the use"/>
 <result pre="to the use of effective antivirals, passive immunotherapy against both" exact="influenza" post="A and B viruses might be the way forward"/>
 <result pre="A and B viruses might be the way forward for" exact="influenza" post="virus management amongst all classes (be it high- or"/>
 <result pre="influenza. Acknowledgments The authors are thankful to The Pirbright Institute’s" exact="avian influenza" post="research team (Jean-Remy Sadeyen, Pengxiang Chang, Sushant Bhat, Joshua"/>
 <result pre="Acknowledgments The authors are thankful to The Pirbright Institute’s avian" exact="influenza" post="research team (Jean-Remy Sadeyen, Pengxiang Chang, Sushant Bhat, Joshua"/>
 <result pre="Epidemiology, pathology, evolution and biological characteristicsVirulence201781580159110.1080/21505594.2017.136521628812422 2.KimuraH.AbikoC.PengG.MurakiY.SugawaraK.HongoS.KitameF.MizutaK.NumazakiY.SuzukiH.et al.Interspecies transmission of" exact="influenza" post="C virus between humans and pigsVirus Res.199748717910.1016/S0168-1702(96)01427-X9140195 3.HinshawV.S.WebsterR.G.EasterdayB.C.BeanW.J.Jr.Replication of"/>
 <result pre="influenza C virus between humans and pigsVirus Res.199748717910.1016/S0168-1702(96)01427-X9140195 3.HinshawV.S.WebsterR.G.EasterdayB.C.BeanW.J.Jr.Replication of" exact="avian influenza" post="A viruses in mammalsInfect. Immun.1981343543617309229 4.OsterhausA.D.RimmelzwaanG.F.MartinaB.E.BestebroerT.M.FouchierR.A.Influenza B virus in"/>
 <result pre="C virus between humans and pigsVirus Res.199748717910.1016/S0168-1702(96)01427-X9140195 3.HinshawV.S.WebsterR.G.EasterdayB.C.BeanW.J.Jr.Replication of avian" exact="influenza" post="A viruses in mammalsInfect. Immun.1981343543617309229 4.OsterhausA.D.RimmelzwaanG.F.MartinaB.E.BestebroerT.M.FouchierR.A.Influenza B virus in"/>
 <result pre="mammalsInfect. Immun.1981343543617309229 4.OsterhausA.D.RimmelzwaanG.F.MartinaB.E.BestebroerT.M.FouchierR.A.Influenza B virus in sealsScience20002881051105310.1126/science.288.5468.105110807575 5.GerhardW.WebsterR.G.Antigenic drift in" exact="influenza" post="A viruses. I. Selection and characterization of antigenic variants"/>
 <result pre="I. Selection and characterization of antigenic variants of A/PR/8/34 (HON1)" exact="influenza" post="virus with monoclonal antibodiesJ. Exp. Med.197814838339210.1084/jem.148.2.383359746 6.YewdellJ.W.WebsterR.G.GerhardW.U.Antigenic variation in"/>
 <result pre="Exp. Med.197814838339210.1084/jem.148.2.383359746 6.YewdellJ.W.WebsterR.G.GerhardW.U.Antigenic variation in three distinct determinants of an" exact="influenza" post="type A haemagglutinin moleculeNature197927924624810.1038/279246a086955 7.HensleyS.E.DasS.R.BaileyA.L.SchmidtL.M.HickmanH.D.JayaramanA.ViswanathanK.RamanR.SasisekharanR.BenninkJ.R.et al.Hemagglutinin Receptor Binding Avidity"/>
 <result pre="Influenza A Virus Antigenic DriftScience200932673473610.1126/science.117825819900932 8.FergusonN.M.GalvaniA.P.BushR.M.Ecological and immunological determinants of" exact="influenza" post="evolutionNature200342242843310.1038/nature0150912660783 9.CarratF.FlahaultA.Influenza vaccine: The challenge of antigenic driftVaccine2007256852686210.1016/j.vaccine.2007.07.02717719149 10.SkehelJ.J.StevensD.J.DanielsR.S.DouglasA.R.KnossowM.WilsonI.A.WileyD.C.A"/>
 <result pre="driftVaccine2007256852686210.1016/j.vaccine.2007.07.02717719149 10.SkehelJ.J.StevensD.J.DanielsR.S.DouglasA.R.KnossowM.WilsonI.A.WileyD.C.A carbohydrate side chain on hemagglutinins of Hong Kong" exact="influenza" post="viruses inhibits recognition by a monoclonal antibodyProc. Natl. Acad."/>
 <result pre="and H3 strains elucidates antigenic shift and drift in human" exact="influenza" post="virusNature198028730130610.1038/287301a07421990 13.DonatelliI.CastrucciM.R.De MarcoM.A.DeloguM.WebsterR.G.Human–Animal Interface: The Case for Influenza Interspecies"/>
 <result pre="and Inactivated Influenza Vaccine in AdultsClin. Vaccine Immunol.201724e00414-1610.1128/CVI.00414-1627847366 17.ShinjohM.SugayaN.YamaguchiY.IibuchiN.KamimakiI.GotoA.KobayashiH.KobayashiY.ShibataM.TamaokaS.et al.Inactivated" exact="influenza" post="vaccine effectiveness and an analysis of repeated vaccination for"/>
 <result pre="for children during the 2016/17 seasonVaccine2018365510551810.1016/j.vaccine.2018.07.06530093289 18.OsterholmM.T.KelleyN.S.SommerA.BelongiaE.A.Efficacy and effectiveness of" exact="influenza" post="vaccines: A systematic review and meta-analysisLancet Infect. Dis.201212364410.1016/S1473-3099(11)70295-X22032844 19.BeyerW.E.P.PalacheA.M.de"/>
 <result pre="A systematic review and meta-analysisLancet Infect. Dis.201212364410.1016/S1473-3099(11)70295-X22032844 19.BeyerW.E.P.PalacheA.M.de JongJ.C.OsterhausA.D.M.E.Cold-adapted live" exact="influenza" post="vaccine versus inactivated vaccine: Systemic vaccine reactions, local and"/>
 <result pre="al.Comparison of the safety, vaccine virus shedding, and immunogenicity of" exact="influenza" post="virus vaccine, trivalent, types A and B, live cold-adapted,"/>
 <result pre="childrenN. Engl. J. Med.19983381405141210.1056/NEJM1998051433820029580647 22.KeitelW.A.CouchR.B.CateT.R.MaassabH.F.Variability in infectivity of cold-adapted recombinant" exact="influenza" post="virus vaccines in humansJ. Infect. Dis.199416947710.1093/infdis/169.2.4778106789 23.GalazkaA.M.LauerB.A.HendersonR.H.KejaJ.Indications and Contraindications"/>
 <result pre="to vaccines practice parameter 2012 updateJ. Allergy Clin. Immunol.2012130254310.1016/j.jaci.2012.04.00322608573 25.OwensG.MacGinnitieA.Higher-ovalbumin-content" exact="influenza" post="vaccines are well tolerated in children with egg allergyJ."/>
 <result pre="children with egg allergyJ. Allergy Clin. Immunol.201112726426510.1016/j.jaci.2010.10.00521094520 26.LiJ.T.RankM.A.SquillaceD.L.KitaH.Ovalbumin content of" exact="influenza" post="vaccinesJ. Allergy Clin. Immunol.20101251412141310.1016/j.jaci.2010.03.00920451987 27.GrohskopfL.A.OlsenS.J.SokolowL.Z.BreseeJ.S.CoxN.J.BroderK.R.KarronR.A.WalterE.B.collab: Centers for Disease Control"/>
 <result pre="J. Transplant.20141429062913 28.StephensonI.NicholsonK.G.GluckR.MischlerR.NewmanR.W.PalacheA.M.VerlanderN.Q.WarburtonF.WoodJ.M.ZambonM.C.Safety and antigenicity of whole virus and subunit" exact="influenza" post="A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: Phase I"/>
 <result pre="healthy adults: Phase I randomised trialLancet20033621959196610.1016/S0140-6736(03)15014-314683655 29.GiezemanK.M.NautaJ.de BruijnI.A.PalacheA.M.Trivalent inactivated subunit" exact="influenza" post="vaccine Influvac (R): 25-Year experience of safety and immunogenicityVaccine2009272414241710.1016/j.vaccine.2009.02.00819368782"/>
 <result pre="25-Year experience of safety and immunogenicityVaccine2009272414241710.1016/j.vaccine.2009.02.00819368782 30.AmbroseC.S.LevinM.J.The rationale for quadrivalent" exact="influenza" post="vaccinesHum. Vaccines Immunother.20128818810.4161/hv.8.1.17623 31.KumarA.MeldgaardT.S.BertholetS.Novel Platforms for the Development of"/>
 <result pre="Vaccines Immunother.20128818810.4161/hv.8.1.17623 31.KumarA.MeldgaardT.S.BertholetS.Novel Platforms for the Development of a Universal" exact="influenza" post="vaccineFront. Immunol.2018960010.3389/fimmu.2018.0060029628926 32.FioreA.E.UyekiT.M.BroderK.FinelliL.EulerG.L.SingletonJ.A.IskanderJ.K.WortleyP.M.ShayD.K.BreseeJ.S.et al.Prevention and control of influenza with"/>
 <result pre="a Universal influenza vaccineFront. Immunol.2018960010.3389/fimmu.2018.0060029628926 32.FioreA.E.UyekiT.M.BroderK.FinelliL.EulerG.L.SingletonJ.A.IskanderJ.K.WortleyP.M.ShayD.K.BreseeJ.S.et al.Prevention and control of" exact="influenza" post="with vaccines: Recommendations of the Advisory Committee on Immunization"/>
 <result pre="in tropical and subtropical areasLancet Respir. Med.2017592092210.1016/S2213-2600(17)30377-629066091 35.DuqueJ.McMorrowM.L.CohenA.L.Influenza vaccines and" exact="influenza" post="antiviral drugs in Africa: Are they available and do"/>
 <result pre="from three H5N1 clades protects chickens from H5N1 and H5N8" exact="influenza" post="virusesVaccine2016341575158110.1016/j.vaccine.2016.02.01126868083 41.WangB.-Z.QuanF.-S.KangS.-M.BozjaJ.SkountzouI.CompansR.W.Incorporation of membrane-anchored flagellin into influenza virus-like particles"/>
 <result pre="H5N1 and H5N8 influenza virusesVaccine2016341575158110.1016/j.vaccine.2016.02.01126868083 41.WangB.-Z.QuanF.-S.KangS.-M.BozjaJ.SkountzouI.CompansR.W.Incorporation of membrane-anchored flagellin into" exact="influenza" post="virus-like particles enhances the breadth of immune responsesJ. Virol.200882118131182310.1128/JVI.01076-0818786995"/>
 <result pre="the breadth of immune responsesJ. Virol.200882118131182310.1128/JVI.01076-0818786995 42.MohanT.BermanZ.LuoY.WangC.WangS.CompansR.W.WangB.Z.Chimeric virus-like particles containing" exact="influenza" post="HA antigen and GPI-CCL28 induce long-lasting mucosal immunity against"/>
 <result pre="viral challengeJ. Virol.2012861029310230110.1128/JVI.01131-1222787224 50.MosslerC.GroissF.WolztM.WolschekM.SeipeltJ.MusterT.Phase I/II trial of a replication-deficient trivalent" exact="influenza" post="virus vaccine lacking NS1Vaccine2013316194620010.1016/j.vaccine.2013.10.06124183981 51.BazM.BoonnakK.PaskelM.SantosC.PowellT.TownsendA.SubbaraoK.Nonreplicating influenza A virus vaccines"/>
 <result pre="of a replication-deficient trivalent influenza virus vaccine lacking NS1Vaccine2013316194620010.1016/j.vaccine.2013.10.06124183981 51.BazM.BoonnakK.PaskelM.SantosC.PowellT.TownsendA.SubbaraoK.Nonreplicating" exact="influenza" post="A virus vaccines confer broad protection against lethal challengeMBio20156e01487-1510.1128/mBio.01487-1526489862"/>
 <result pre="Induced by a Single-Cycle Influenza VaccineJ. Immunol.20182004068407710.4049/jimmunol.180014229703861 53.NachbagauerR.LiuW.C.ChoiA.WohlboldT.J.AtlasT.RajendranM.SolórzanoA.Berlanda-ScorzaF.García-SastreA.PaleseP.et al.A universal" exact="influenza" post="virus vaccine candidate confers protection against pandemic H1N1 infection"/>
 <result pre="in preclinical ferret studiesNpj Vaccines201722610.1038/s41541-017-0026-429263881 54.ImpagliazzoA.MilderF.KuipersH.WagnerM.V.ZhuX.Y.HoffmanR.M.B.van MeersbergenR.HuizinghJ.WanningenP.VerspuijJ.et al.A stable trimeric" exact="influenza" post="hemagglutinin stem as a broadly protective immunogenScience20153491301130610.1126/science.aac726326303961 55.CorreiaB.E.BatesJ.T.LoomisR.J.BaneyxG.CarricoC.JardineJ.G.RupertP.CorrentiC.KalyuzhniyO.VittalV.et al.Proof"/>
 <result pre="57.ThompsonC.P.LourencoJ.WaltersA.A.ObolskiU.EdmansM.PalmerD.S.KooblallK.CarnellG.W.O’ConnorD.BowdenT.A.et al.A naturally protective epitope of limited variability as an" exact="influenza" post="vaccine targetNat. Commun.20189385910.1038/s41467-018-06228-830242149 58.AtsmonJ.Kate-IlovitzE.ShaikevichD.SingerY.VolokhovI.HaimK.Y.Ben-YedidiaT.Safety and immunogenicity of multimeric-001—A novel"/>
 <result pre="vaccine targetNat. Commun.20189385910.1038/s41467-018-06228-830242149 58.AtsmonJ.Kate-IlovitzE.ShaikevichD.SingerY.VolokhovI.HaimK.Y.Ben-YedidiaT.Safety and immunogenicity of multimeric-001—A novel universal" exact="influenza" post="vaccineJ. Clin. Immunol.20123259560310.1007/s10875-011-9632-522318394 59.FonteneauJ.-F.GillietM.LarssonM.DasilvaI.MünzC.LiuY.-J.BhardwajN.Activation of influenza virus–specific CD4+ and"/>
 <result pre="of multimeric-001—A novel universal influenza vaccineJ. Clin. Immunol.20123259560310.1007/s10875-011-9632-522318394 59.FonteneauJ.-F.GillietM.LarssonM.DasilvaI.MünzC.LiuY.-J.BhardwajN.Activation of" exact="influenza" post="virus–specific CD4+ and CD8+ T cells: A new role"/>
 <result pre="role for plasmacytoid dendritic cells in adaptive immunityBlood20031013520352610.1182/blood-2002-10-306312511409 60.Abdel-MotalU.M.GuayH.M.WigglesworthK.WelshR.M.GaliliU.Immunogenicity of" exact="influenza" post="virus vaccine is increased by anti-gal-mediated targeting to antigen-presenting"/>
 <result pre="APC surface molecules influences the immune response phenotypePLoS ONE20138e8000810.1371/journal.pone.008000824244595 62.KanekiyoM.WeiC.J.YassineH.M.McTamneyP.M.BoyingtonJ.C.WhittleJ.R.RaoS.S.KongW.P.WangL.NabelG.J.Self-assembling" exact="influenza" post="nanoparticle vaccines elicit broadly neutralizing H1N1 antibodiesNature201349910210610.1038/nature1220223698367 63.DengL.ChoK.J.FiersW.SaelensX.M2e-Based Universal"/>
 <result pre="antibodiesNature201349910210610.1038/nature1220223698367 63.DengL.ChoK.J.FiersW.SaelensX.M2e-Based Universal Influenza A VaccinesVaccines2015310513610.3390/vaccines301010526344949 64.TaoW.Q.GillH.S.M2e-immobilized gold nanoparticles as" exact="influenza" post="A vaccine: Role of soluble M2e and longevity of"/>
 <result pre="Sci. USA20161134133414210.1073/pnas.1600299113 67.DengL.MohanT.ChangT.Z.GonzalezG.X.WangY.KwonY.M.KangS.M.CompansR.W.ChampionJ.A.WangB.Z.Double-layered protein nanoparticles induce broad protection against divergent" exact="influenza" post="A virusesNat. Commun.20182435910.1038/s41467-017-02725-429367723 68.HardingA.T.HeatonN.S.Efforts to Improve the Seasonal Influenza"/>
 <result pre="al.Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic" exact="influenza" post="A vaccine, MVA-NP+M1Clin. Infect. Dis.2011521710.1093/cid/ciq01521148512 71.AntrobusR.D.BerthoudT.K.MullarkeyC.E.HoschlerK.CoughlanL.ZambonM.HillA.V.GilbertS.C.Coadministration of seasonal influenza"/>
 <result pre="heterosubtypic influenza A vaccine, MVA-NP+M1Clin. Infect. Dis.2011521710.1093/cid/ciq01521148512 71.AntrobusR.D.BerthoudT.K.MullarkeyC.E.HoschlerK.CoughlanL.ZambonM.HillA.V.GilbertS.C.Coadministration of seasonal" exact="influenza" post="vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated"/>
 <result pre="of an Adenoviral Vectored Multivalent Centralized Influenza VaccineSci. Rep.201771491210.1038/s41598-017-14891-y29097763 74.TrippR.A.TompkinsS.M.Virus-vectored" exact="influenza" post="virus vaccinesViruses201463055307910.3390/v608305525105278 75.GubarevaL.V.KaiserL.HaydenF.G.Influenza virus neuraminidase inhibitorsLancet200035582783510.1016/S0140-6736(99)11433-810711940 76.PintoL.H.DieckmannG.R.GandhiC.S.PapworthC.G.BramanJ.ShaughnessyM.A.LearJ.D.LambR.A.DeGradoW.F.A functionally defined"/>
 <result pre="76.PintoL.H.DieckmannG.R.GandhiC.S.PapworthC.G.BramanJ.ShaughnessyM.A.LearJ.D.LambR.A.DeGradoW.F.A functionally defined model for the M2 proton channel of" exact="influenza" post="A virus suggests a mechanism for its ion selectivityProc."/>
 <result pre="ion channel activityCell19926951752810.1016/0092-8674(92)90452-I1374685 78.MaC.PolishchukA.L.OhigashiY.StoufferA.L.SchönA.MagavernE.JingX.LearJ.D.FreireE.LambR.A.Identification of the functional core of the" exact="influenza" post="A virus A/M2 proton-selective ion channelProc. Natl. Acad. Sci."/>
 <result pre="Natl. Acad. Sci. USA2009106122831228810.1073/pnas.090572610619590009 79.Van VorisL.P.BettsR.F.HaydenF.G.ChristmasW.A.DouglasR.G.Jr.Successful treatment of naturally occurring" exact="influenza" post="A/USSR/77 H1N1JAMA19812451128123110.1001/jama.1981.033103600200167007668 80.BeanW.J.ThrelkeldS.C.WebsterR.G.Biologic potential of amantadine-resistant influenza A virus"/>
 <result pre="of naturally occurring influenza A/USSR/77 H1N1JAMA19812451128123110.1001/jama.1981.033103600200167007668 80.BeanW.J.ThrelkeldS.C.WebsterR.G.Biologic potential of amantadine-resistant" exact="influenza" post="A virus in an avian modelJ. Infect. Dis.19891591050105610.1093/infdis/159.6.10502723453 81.DeydeV.M.XuX.Y.BrightR.A.ShawM.SmithC.B.ZhangY.ShuY.GubarevaL.V.CoxN.J.KlimovA.I.Surveillance"/>
 <result pre="avian modelJ. Infect. Dis.19891591050105610.1093/infdis/159.6.10502723453 81.DeydeV.M.XuX.Y.BrightR.A.ShawM.SmithC.B.ZhangY.ShuY.GubarevaL.V.CoxN.J.KlimovA.I.Surveillance of resistance to adamantanes among" exact="influenza" post="A(H3N2) and A(H1N1) viruses isolated worldwideJ. Infect. Dis.200719624925710.1086/51893617570112 82.HussainM.GalvinH.D.HawT.Y.NutsfordA.N.HusainM.Drug"/>
 <result pre="and A(H1N1) viruses isolated worldwideJ. Infect. Dis.200719624925710.1086/51893617570112 82.HussainM.GalvinH.D.HawT.Y.NutsfordA.N.HusainM.Drug resistance in" exact="influenza" post="A virus: The epidemiology and managementInfect. Drug Resist.20171012113410.2147/IDR.S10547328458567 83.McKimm-BreschkinJ.L.Neuraminidase"/>
 <result pre="84.Rameix-WeltiM.A.EnoufV.CuvelierF.JeanninP.van der WerfS.Enzymatic properties of the neuraminidase of seasonal H1N1" exact="influenza" post="viruses provide insights for the emergence of natural resistance"/>
 <result pre="Virol.20094425526110.1016/j.jcv.2009.01.01019272835 86.SamsonM.PizzornoA.AbedY.BoivinG.Influenza virus resistance to neuraminidase inhibitorsAntivir. Res.20139817418510.1016/j.antiviral.2013.03.01423523943 87.NoahD.L.NoahJ.W.Adapting global" exact="influenza" post="management strategies to address emerging virusesAm. J. Physiol.-Lung Cell."/>
 <result pre="Physiol.-Lung Cell. Mol. Physiol.201330510811710.1152/ajplung.00105.201323709619 88.NguyenH.T.NguyenT.MishinV.P.SleemanK.BalishA.JonesJ.CreangaA.MarjukiH.UyekiT.M.NguyenD.H.et al.Antiviral susceptibility of highly pathogenic" exact="avian influenza" post="A(H5N1) viruses isolated from poultry, Vietnam, 2009–2011Emerg. Infect. Dis.2013191963197110.3201/eid1912.13070524274711"/>
 <result pre="Cell. Mol. Physiol.201330510811710.1152/ajplung.00105.201323709619 88.NguyenH.T.NguyenT.MishinV.P.SleemanK.BalishA.JonesJ.CreangaA.MarjukiH.UyekiT.M.NguyenD.H.et al.Antiviral susceptibility of highly pathogenic avian" exact="influenza" post="A(H5N1) viruses isolated from poultry, Vietnam, 2009–2011Emerg. Infect. Dis.2013191963197110.3201/eid1912.13070524274711"/>
 <result pre="89.MalakhovM.P.AschenbrennerL.M.SmeeD.F.WanderseeM.K.SidwellR.W.GubarevaL.V.MishinV.P.HaydenF.G.KimD.H.IngA.et al.Sialidase fusion protein as a novel broad-spectrum inhibitor of" exact="influenza" post="virus infectionAntimicrob. Agents Chemother.2006501470147910.1128/AAC.50.4.1470-1479.200616569867 90.BaumL.G.PaulsonJ.C.Sialyloligosaccharides of the respiratory epithelium"/>
 <result pre="90.BaumL.G.PaulsonJ.C.Sialyloligosaccharides of the respiratory epithelium in the selection of human" exact="influenza" post="virus receptor specificityActa Histochem. Suppl.19904035382091044 91.BelserJ.A.LuX.SzretterK.J.JinX.AschenbrennerL.M.LeeA.HawleyS.KimD.H.MalakhovM.P.YuM.et al.DAS181, a novel"/>
 <result pre="al.DAS181, a novel sialidase fusion protein, protects mice from lethal" exact="avian influenza" post="H5N1 virus infectionJ. Infect. Dis.20071961493149910.1086/52260918008229 92.ChanR.W.ChanM.C.WongA.C.KaramanskaR.DellA.HaslamS.M.SihoeA.D.ChuiW.H.Triana-BaltzerG.LiQ.et al.DAS181 inhibits H5N1"/>
 <result pre="a novel sialidase fusion protein, protects mice from lethal avian" exact="influenza" post="H5N1 virus infectionJ. Infect. Dis.20071961493149910.1086/52260918008229 92.ChanR.W.ChanM.C.WongA.C.KaramanskaR.DellA.HaslamS.M.SihoeA.D.ChuiW.H.Triana-BaltzerG.LiQ.et al.DAS181 inhibits H5N1"/>
 <result pre="influenza H5N1 virus infectionJ. Infect. Dis.20071961493149910.1086/52260918008229 92.ChanR.W.ChanM.C.WongA.C.KaramanskaR.DellA.HaslamS.M.SihoeA.D.ChuiW.H.Triana-BaltzerG.LiQ.et al.DAS181 inhibits H5N1" exact="influenza" post="virus infection of human lung tissuesAntimicrob. Agents Chemother.2009533935394110.1128/AAC.00389-0919596886 93.Triana-BaltzerG.B.BabizkiM.ChanM.C.WongA.C.AschenbrennerL.M.CampbellE.R.LiQ.X.ChanR.W.PeirisJ.S.NichollsJ.M.et"/>
 <result pre="al.DAS181, a sialidase fusion protein, protects human airway epithelium against" exact="influenza" post="virus infection: An in vitro pharmacodynamic analysisJ. Antimicrob. Chemother.20106527528410.1093/jac/dkp42119942616"/>
 <result pre="activity of VX-787, a first-in-class, orally bioavailable inhibitor of the" exact="influenza" post="virus polymerase PB2 subunitAntimicrob. Agents Chemother.2015591569158210.1128/AAC.04623-1425547360 98.SmeeD.F.BarnardD.L.JonesS.M.Activities of JNJ63623872"/>
 <result pre="PB2 subunitAntimicrob. Agents Chemother.2015591569158210.1128/AAC.04623-1425547360 98.SmeeD.F.BarnardD.L.JonesS.M.Activities of JNJ63623872 and oseltamivir against" exact="influenza" post="A H1N1pdm and H3N2 virus infections in miceAntivir. Res.2016136455010.1016/j.antiviral.2016.10.00927771390"/>
 <result pre="H1N1pdm and H3N2 virus infections in miceAntivir. Res.2016136455010.1016/j.antiviral.2016.10.00927771390 99.FuY.GaelingsL.SoderholmS.BelanovS.NandaniaJ.NymanT.A.MatikainenS.AndersS.VelagapudiV.KainovD.E.JNJ872 inhibits" exact="influenza" post="A virus replication without altering cellular antiviral responsesAntivir. Res.2016133233110.1016/j.antiviral.2016.07.00827451344"/>
 <result pre="RNA viral infectionsAntivir. Res.2009829510210.1016/j.antiviral.2009.02.19819428599 102.FurutaY.TakahashiK.Kuno-MaekawaM.SangawaH.UeharaS.KozakiK.NomuraN.EgawaH.ShirakiK.Mechanism of action of T-705 against" exact="influenza" post="virusAntimicrob. Agents Chemother.20054998198610.1128/AAC.49.3.981-986.200515728892 103.BaranovichT.WongS.S.ArmstrongJ.MarjukiH.WebbyR.J.WebsterR.G.GovorkovaE.A.T-705 (favipiravir) induces lethal mutagenesis in"/>
 <result pre="influenza virusAntimicrob. Agents Chemother.20054998198610.1128/AAC.49.3.981-986.200515728892 103.BaranovichT.WongS.S.ArmstrongJ.MarjukiH.WebbyR.J.WebsterR.G.GovorkovaE.A.T-705 (favipiravir) induces lethal mutagenesis in" exact="influenza" post="A H1N1 viruses in vitroJ. Virol.2013873741375110.1128/JVI.02346-1223325689 104.JinZ.SmithL.K.RajwanshiV.K.KimB.DevalJ.The ambiguous base-pairing"/>
 <result pre="and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5′-triphosphate towards" exact="influenza" post="A virus polymerasePLoS ONE20138e6834710.1371/journal.pone.006834723874596 105.NaesensL.GuddatL.W.KeoughD.T.van KuilenburgA.B.MeijerJ.Vande VoordeJ.BalzariniJ.Role of human"/>
 <result pre="Adults and AdolescentsN. Engl. J. Med.201837991392310.1056/NEJMoa171619730184455 115.O’HanlonR.ShawM.L.Baloxavir marboxil: The new" exact="influenza" post="drug on the marketCurr. Opin. Virol.201935141810.1016/j.coviro.2019.01.00630852344 116.GagarinovaV.M.Ignat’evaG.S.SinitskaiaL.V.IvanovaA.M.RodinaM.A.Tur’evaA.V.The new chemical"/>
 <result pre="Virol.201935141810.1016/j.coviro.2019.01.00630852344 116.GagarinovaV.M.Ignat’evaG.S.SinitskaiaL.V.IvanovaA.M.RodinaM.A.Tur’evaA.V.The new chemical preparation arbidol: Its prophylactic efficacy during" exact="influenza" post="epidemicsZh Mikrobiol. Epidemiol. Immunobiol.199354043 117.BoriskinY.S.LenevaI.A.PecheurE.I.PolyakS.J.Arbidol: A broad-spectrum antiviral compound"/>
 <result pre="FlavivirusesViruses20181018410.3390/v10040184 122.LoginovaS.BorisevichS.V.MaksimovV.A.BondarevV.P.Nebol’sinV.E.Therapeutic efficacy of Ingavirin, a new domestic formulation against" exact="influenza" post="A virus (H3N2)Antibiot Khimioter200853273019227120 123.GalegovG.A.AndronovaV.L.Nebol’sinV.E.Antiviral effect of Ingavirin against"/>
 <result pre="A virus (H3N2)Antibiot Khimioter200853273019227120 123.GalegovG.A.AndronovaV.L.Nebol’sinV.E.Antiviral effect of Ingavirin against seasonal" exact="influenza" post="virus A/H1N1 in MDCK cell cultureAntibiot Khimioter2009541922 124.ZarubaevV.V.BeliaevskaiaS.V.SirotkinA.K.AnfimovP.M.Nebol’sinV.E.KiselevO.I.ReĭkhartD.V.In vitro"/>
 <result pre="vivo effects of ingavirin on the ultrastructure and infectivity of" exact="influenza" post="virusVopr. Virusol.201156212522171473 125.SimoesE.A.GroothuisJ.R.Carbonell-EstranyX.RiegerC.H.MitchellI.FredrickL.M.KimpenJ.L.collab: Palivizumab Long-Term Respiratory Outcomes Study GroupPalivizumab"/>
 <result pre="broadly neutralizing stem antibody in complex with a pandemic H2" exact="influenza" post="virus hemagglutininJ. Virol.2013877149715410.1128/JVI.02975-1223552413 129.ThrosbyM.van den BrinkE.JongeneelenM.PoonL.L.M.AlardP.CornelissenL.BakkerA.CoxF.van DeventerE.GuanY.et al.Heterosubtypic Neutralizing"/>
 <result pre="Acute Uncomplicated InfluenzaAntimicrob. Agents Chemother.201862e00694-1810.1128/AAC.00694-1830150460 132.PappasL.FoglieriniM.PiccoliL.KallewaardN.L.TurriniF.SilacciC.Fernandez-RoadriguezB.AgaticG.Giacchetto-SasselliI.PellicciottaG.et al.Rapid development of broadly" exact="influenza" post="neutralizing antibodies through redundant mutationsNature201451641842210.1038/nature1376425296253 133.LuJ.GuoZ.PanX.WangG.ZhangD.LiY.TanB.OuyangL.YuX.Passive immunotherapy for influenza"/>
 <result pre="broadly influenza neutralizing antibodies through redundant mutationsNature201451641842210.1038/nature1376425296253 133.LuJ.GuoZ.PanX.WangG.ZhangD.LiY.TanB.OuyangL.YuX.Passive immunotherapy for" exact="influenza" post="A H5N1 virus infection with equine hyperimmune globulin F"/>
 <result pre="neutralizing antibodies are produced by individuals immunized with a seasonal" exact="influenza" post="vaccineJ. Clin. Investig.20101201663167310.1172/JCI4190220389023 136.MargineI.KrammerF.HaiR.HeatonN.TanG.AndrewsS.RunstadlerJ.A.WilsonP.C.AlbrechtR.A.Garcia-SastreA.et al.Hemagglutinin stalk-based universal vaccine constructs"/>
 <result pre="136.MargineI.KrammerF.HaiR.HeatonN.TanG.AndrewsS.RunstadlerJ.A.WilsonP.C.AlbrechtR.A.Garcia-SastreA.et al.Hemagglutinin stalk-based universal vaccine constructs protect against group 2" exact="influenza" post="A virusesJ. Virol.201310.1128/JVI.01715-1323903831 137.NachbagauerR.MillerM.S.HaiR.RyderA.B.RoseJ.K.PaleseP.García-SastreA.KrammerF.AlbrechtR.A.Hemagglutinin stalk immunity reduces influenza virus"/>
 <result pre="group 2 influenza A virusesJ. Virol.201310.1128/JVI.01715-1323903831 137.NachbagauerR.MillerM.S.HaiR.RyderA.B.RoseJ.K.PaleseP.García-SastreA.KrammerF.AlbrechtR.A.Hemagglutinin stalk immunity reduces" exact="influenza" post="virus replication and transmission in ferretsJ. Virol.2016903268327310.1128/JVI.02481-15 138.WohlboldT.J.NachbagauerR.MargineI.TanG.S.HirshA.KrammerF.Vaccination with"/>
 <result pre="with soluble headless hemagglutinin protects mice from challenge with divergent" exact="influenza" post="virusesVaccine2015333314332110.1016/j.vaccine.2015.05.03826026378 139.El BakkouriK.DescampsF.De FiletteM.SmetA.FestjensE.BirkettA.Van RooijenN.VerbeekS.FiersW.SaelensX.Universal vaccine based on ectodomain"/>
 <result pre="RooijenN.VerbeekS.FiersW.SaelensX.Universal vaccine based on ectodomain of matrix protein 2 of" exact="influenza" post="A: Fc receptors and alveolar macrophages mediate protectionJ. Immunol.20111861022103110.4049/jimmunol.090214721169548"/>
 <result pre="Fc receptors and alveolar macrophages mediate protectionJ. Immunol.20111861022103110.4049/jimmunol.090214721169548 140.WilsonJ.R.BelserJ.A.DaSilvaJ.GuoZ.SunX.GansebomS.BaiY.StarkT.J.ChangJ.CarneyP.et al.An" exact="influenza" post="A virus (H7N9) anti-neuraminidase monoclonal antibody protects mice from"/>
 <result pre="virus disease in nonhuman primates with ZMappNature2014514475310.1038/nature1377725171469 144.BalazsA.B.BloomJ.D.HongC.M.RaoD.S.BaltimoreD.Broad protection against" exact="influenza" post="infection by vectored immunoprophylaxis in miceNat. Biotechnol.20133164765210.1038/nbt.261823728362 145.BerryC.M.PenhaleW.J.SangsterM.Y.Passive broad-spectrum"/>
 <result pre="influenza infection by vectored immunoprophylaxis in miceNat. Biotechnol.20133164765210.1038/nbt.261823728362 145.BerryC.M.PenhaleW.J.SangsterM.Y.Passive broad-spectrum" exact="influenza" post="immunoprophylaxisInfluenza. Res. Treat.2014201426759410.1155/2014/26759425328697 146.ZhouB.ZhongN.GuanY.Treatment with convalescent plasma for influenza"/>
 <result pre="broad-spectrum influenza immunoprophylaxisInfluenza. Res. Treat.2014201426759410.1155/2014/26759425328697 146.ZhouB.ZhongN.GuanY.Treatment with convalescent plasma for" exact="influenza" post="A (H5N1) infectionN. Engl. J. Med.20073571450145110.1056/NEJMc07035917914053 147.JegerlehnerA.SchmitzN.StorniT.BachmannM.F.Influenza A vaccine"/>
 <result pre="in both protection against and recovery from pulmonary infection with" exact="influenza" post="virus in miceJ. Virol.2008822772278310.1128/JVI.01210-0718184718 149.TerajimaM.CoM.D.T.CruzJ.EnnisF.A.High Antibody-Dependent Cellular Cytotoxicity Antibody"/>
 <result pre="150.YuX.TsibaneT.McGrawP.A.HouseF.S.KeeferC.J.HicarM.D.TumpeyT.M.PappasC.PerroneL.A.MartinezO.et al.Neutralizing antibodies derived from the B cells of 1918" exact="influenza" post="pandemic survivorsNature200845553210.1038/nature0723118716625 151.KrammerF.García-SastreA.PaleseP.Is it possible to develop a &quot;universal�?"/>
 <result pre="influenza pandemic survivorsNature200845553210.1038/nature0723118716625 151.KrammerF.García-SastreA.PaleseP.Is it possible to develop a &quot;universal�?" exact="influenza" post="virus vaccine? Toward a universal influenza virus vaccine: Potential"/>
 <result pre="to develop a &quot;universal�? influenza virus vaccine? Toward a universal" exact="influenza" post="virus vaccine: Potential target antigens and critical aspects for"/>
 <result pre="antibody-dependent cell lysis (ADCL). vaccines-07-00053-t001_Table 1Table 1 Summary of novel" exact="influenza" post="virus vaccine platforms. Vaccines Design References Virus-like particle vaccines"/>
 <result pre="inhibition III completed USA JNJ-63623872 (Pimodivir) Small molecule inhibitor of" exact="influenza" post="A virus PB2 III recruiting Belgium T705 (Favipiravir) RNA-dependent"/>
 <result pre="from the clinicaltrials.gov. 1 Approved for treatment of acute uncomplicated" exact="influenza" post="among ≥12 years vaccines-07-00053-t003_Table 3Table 3 Antibodies undergoing clinical"/>
</results>
